Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 5, 26 | Thaysen Jacob | director, officer: Chief Executive Officer | F-InKind | 1,303 @ $293.69 | $382.7K |
Daily · Wilder smoothing
| Sep 30, 26 |
| Meister Keith A. |
| director |
| A-Award |
| 107 @ $219.80 |
| $23.52K |
| Sep 30, 26 | Ullem Scott B. | director | A-Award | 113 @ $219.80 | $24.84K |
| Sep 8, 26 | Coletti Julie Ann | officer: Chief Legal Officer | A-Award | 14,214 | — |
| Sep 8, 26 | Coletti Julie Ann | officer: Chief Legal Officer | A-Award | 5,307 | — |
| Sep 8, 26 | Coletti Julie Ann | officer: Chief Legal Officer | A-Award | 4,549 | — |
| Sep 5, 26 | Barnard Steven | officer: SVP, Chief Technology Officer | F-InKind | 408 @ $211.06 | $86.11K |
| Sep 2, 26 | Meister Keith A. | director | S-Sale | 57,488 @ $213.20 | $12.26M |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 55.11 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 36.50 | Oscillator | Neutral |
| Williams %R (14) | -70.46 | Oscillator | Neutral |
| MACD (12, 26, 9) | 7.81 (Hist -2.29) | Oscillator | Sell |
| Average Directional Index (14) | 36.47 (+DI 24.1 / -DI 13.3) | Trend | Strong Buy |
| EMA 20 | 266.13 | MA | Buy |
| SMA 20 | 271.87 | MA | Sell |
| EMA 50 | 245.62 | MA | Strong Buy |
| SMA 50 | 241.82 | MA | Strong Buy |
| SMA 200 | 172.90 | MA | Strong Buy |
FY2025 · 10-K disclosure
FY2025 · 10-K disclosure
Stock news · updated daily
Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Illumina (ILMN) is rated a Buy, driven by robust demand for consumables and NovaSeq X instruments, supported by favorable market dynamics and regulatory tailwinds. NovaSeq X accounts for 59% of consumable revenues, up from 44% in Q2'25, highlighting strong uptake and positioning ILMN to capture expanding diagnostic consumables market share. Management guides for FY2026 revenue of $4.60–$4.64 billion and analysts expect EPS of $5.36, reflecting double-digit upside with a fair forward P/S target of 9.75x ($293.77).
Illumina's Q3 results may benefit from strong clinical demand, NovaSeq X adoption, instrument placements and innovations despite persistent weakness in research markets.
DRAGEN Ultra, BioInsight Platform Workflow Orchestrator, and BioInsight Platform Learning Cohorts are now available in early access, incorporating new AI-driven approaches to analysis, automation, and discovery The tools automate end-to-end informatics processes at scale and help customers build private data lakes to drive scientific and clinical research insights SAN DIEGO, Oct. 21, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today introduced three early-access capabilities on its BioInsight Platform that help researchers move faster from sequencing data to discovery. BioInsight Platform Workflow Orchestrator enables laboratories to operate consistent, traceable sequencing and informatics operations at scale.
SAN DIEGO, Oct. 20, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that members of its management team will participate at the following investor conference: Upcoming Investor Conference UBS Global Healthcare Conference on November 10, 2026 The fireside chat is scheduled for 07:15am PT (10:15am ET). The webcast can be accessed through the Events & Presentations section of Illumina's website at investor.illumina.com.
Rate and energy headlines have kept the broad market jumpy, yet one sector keeps finding buyers. Healthcare has led on days when the S&P 500 slipped, and the Nasdaq Biotechnology Index has pushed to record highs.
First Citizens Bank and Trust Co. purchased a new position in Illumina, Inc. (NASDAQ: ILMN) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 3,511 shares of the life sciences company's stock, valued at approximately $961,000. A number of
Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Jul 30, 2026 | 1.23 | 1.31 | Beat 6.5% | $1.16B |
| Apr 30, 2026 | 1.05 | 1.15 | Beat 9.5% | $1.09B |
| Feb 5, 2026 | 1.24 | 1.35 | Beat 8.9% | $1.16B |
| Oct 30, 2025 | 1.17 | 1.34 | Beat 14.5% | $1.08B |
| Jul 31, 2025 | 1.02 | 1.19 | Beat 16.7% | $1.06B |
| May 8, 2025 | 0.94 | 0.97 | Beat 3.2% | $1.04B |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 8-K | Oct 13, 2026 | 2026-10-13 16:48:27 | View |
| 4 | Oct 7, 2026 | 2026-10-07 16:56:46 | View |
| SC 13G | Oct 7, 2026 | 2026-10-07 11:47:11 | View |
| 4 | Oct 2, 2026 | 2026-10-02 20:12:04 | View |
| 4 | Oct 2, 2026 | 2026-10-02 19:56:07 | View |
| 4 | Sep 10, 2026 | 2026-09-10 16:59:03 | View |
| 4 | Sep 9, 2026 | 2026-09-09 16:38:05 | View |
| 4 | Sep 4, 2026 | 2026-09-04 18:43:37 | View |
| 4 | Aug 27, 2026 | 2026-08-27 19:35:51 | View |
| 4 | Aug 21, 2026 | 2026-08-21 19:42:29 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | ILMN | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 50.0x | 10.9x · sector 20.7x | Elevated |
| Forward P/E (FY26E) | 50.5x | EPS est. 5.36 | In line |
| Price / Book | 14.4x | 6.0x | Elevated |
| Price / Sales | 9.1x | 6.7x | Elevated |
| EV / EBITDA | 31.0x | -2.8x | Discount |
| Return on equity | 31.1% | — | Top tier |
| Gross margin | 66.8% | 65.5% | In line |
| Debt / Equity | 0.89 | 0.64 | Moderate |
| Piotroski / Altman Z | 6/9 | Z 7.84 | Safe zone |
Discounted cash flow model
Current price $270.42
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 19, 26 | Canaccord Genuity | maintain | Hold | Hold |
| Oct 13, 26 | TD Cowen | maintain | Hold | Hold |
| Oct 7, 26 | Barclays | maintain | Underweight | Underweight |
| Oct 5, 26 | RBC Capital | maintain | Outperform | Outperform |
| Oct 1, 26 | Guggenheim | maintain | Buy | Buy |
| Sep 29, 26 | Leerink Partners | maintain | Outperform | Outperform |
| Sep 28, 26 | Piper Sandler | maintain | Overweight | Overweight |
| Sep 9, 26 | UBS | upgrade | Neutral | Buy |
| Sep 3, 26 | Argus Research | maintain | Buy | Buy |